Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA.

Am J Hum Genet. 2000 Apr;66(4):1259-72. Epub 2000 Mar 16.

2.

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D.

Am J Hum Genet. 1997 May;60(5):1059-67.

3.

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.

Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM.

J Med Genet. 1999 May;36(5):369-73.

4.

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Roa BB, Boyd AA, Volcik K, Richards CS.

Nat Genet. 1996 Oct;14(2):185-7.

PMID:
8841191
5.

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.

Am J Hum Genet. 1997 Mar;60(3):505-14.

6.

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA.

Am J Hum Genet. 1999 Apr;64(4):963-70.

7.

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.

Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E.

Hum Mutat. 2000 Dec;16(6):491-501.

PMID:
11102978
8.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

9.

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.

Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K.

Nat Genet. 1996 Oct;14(2):188-90.

PMID:
8841192
10.

Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.

Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ.

Gynecol Oncol. 2000 Aug;78(2):148-51.

PMID:
10926794
11.

Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM.

Am J Hum Genet. 1998 Jul;63(1):45-51.

12.

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.

Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E.

Br J Cancer. 2000 Aug;83(4):463-6.

13.

A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.

Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC.

Obstet Gynecol. 1999 Jan;93(1):34-7.

PMID:
9916952
14.

An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.

Lalloo F, Cochrane S, Bulman B, Varley J, Elles R, Howell A, Evans DG.

J Med Genet. 1998 Jan;35(1):10-2.

15.

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K.

Nat Genet. 1996 May;13(1):126-8.

PMID:
8673092
16.

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S.

J Natl Cancer Inst. 1999 Jul 21;91(14):1241-7.

PMID:
10413426
17.

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.

Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.

Neoplasma. 2006;53(2):97-102.

PMID:
16575464
18.

The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.

Kreiss Y, Barak F, Baruch RG, Levy-Lahad E, Pras E, Friedman E.

Genet Test. 2000;4(4):403-7.

PMID:
11216667
19.

Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.

Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B.

Gynecol Oncol. 2000 Oct;79(1):74-8.

PMID:
11006035
20.

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA.

N Engl J Med. 1997 May 15;336(20):1401-8.

Supplemental Content

Support Center